Sarit Sara Sivan1, Ellen Wachtel2, Peter Roughley3. 1. Department of Biotechnology Engineering, ORT Braude College, Karmiel 21982 Israel. Electronic address: ssivan@braude.ac.il. 2. Faculty of Chemistry, Weizmann Institute of Science, Rehovot 76100, Israel. 3. Shriners Hospital for Children, Genetics Unit, 1529 Cedar Avenue, Montreal, Quebec H3G 1A6, Canada.
Abstract
BACKGROUND: Aggrecan is the major non-collagenous component of the intervertebral disc. It is a large proteoglycan possessing numerous glycosaminoglycan chains and the ability to form aggregates in association with hyaluronan. Its abundance and unique molecular features provide the disc with its osmotic properties and ability to withstand compressive loads. Degradation and loss of aggrecan result in impairment of disc function and the onset of degeneration. SCOPE OF REVIEW: This review summarizes current knowledge concerning the structure and function of aggrecan in the normal intervertebral disc and how and why these change in aging and degenerative disc disease. It also outlines how supplementation with aggrecan or a biomimetic may be of therapeutic value in treating the degenerate disc. MAJOR CONCLUSIONS: Aggrecan abundance reaches a plateau in the early twenties, declining thereafter due to proteolysis, mainly by matrix metalloproteinases and aggrecanases, though degradation of hyaluronan and non-enzymic glycation may also participate. Aggrecan loss is an early event in disc degeneration, although it is a lengthy process as degradation products may accumulate in the disc for decades. The low turnover rate of the remaining aggrecan is an additional contributing factor, preventing protein renewal. It may be possible to retard the degenerative process by restoring the aggrecan content of the disc, or by supplementing with a bioimimetic possessing similar osmotic properties. GENERAL SIGNIFICANCE: This review provides a basis for scientists and clinicians to understand and appreciate the central role of aggrecan in the function, degeneration and repair of the intervertebral disc.
BACKGROUND: Aggrecan is the major non-collagenous component of the intervertebral disc. It is a large proteoglycan possessing numerous glycosaminoglycan chains and the ability to form aggregates in association with hyaluronan. Its abundance and unique molecular features provide the disc with its osmotic properties and ability to withstand compressive loads. Degradation and loss of aggrecan result in impairment of disc function and the onset of degeneration. SCOPE OF REVIEW: This review summarizes current knowledge concerning the structure and function of aggrecan in the normal intervertebral disc and how and why these change in aging and degenerative disc disease. It also outlines how supplementation with aggrecan or a biomimetic may be of therapeutic value in treating the degenerate disc. MAJOR CONCLUSIONS: Aggrecan abundance reaches a plateau in the early twenties, declining thereafter due to proteolysis, mainly by matrix metalloproteinases and aggrecanases, though degradation of hyaluronan and non-enzymic glycation may also participate. Aggrecan loss is an early event in disc degeneration, although it is a lengthy process as degradation products may accumulate in the disc for decades. The low turnover rate of the remaining aggrecan is an additional contributing factor, preventing protein renewal. It may be possible to retard the degenerative process by restoring the aggrecan content of the disc, or by supplementing with a bioimimetic possessing similar osmotic properties. GENERAL SIGNIFICANCE: This review provides a basis for scientists and clinicians to understand and appreciate the central role of aggrecan in the function, degeneration and repair of the intervertebral disc.
Authors: Daniel L Belavý; Kirsten Albracht; Gert-Peter Bruggemann; Pieter-Paul A Vergroesen; Jaap H van Dieën Journal: Sports Med Date: 2016-04 Impact factor: 11.136
Authors: B A Walter; D Purmessur; A Moon; J Occhiogrosso; D M Laudier; A C Hecht; J C Iatridis Journal: Eur Cell Mater Date: 2016-07-19 Impact factor: 3.942
Authors: Guus G H van den Akker; Lars M T Eijssen; Stephen M Richardson; Lodewijk W van Rhijn; Judith A Hoyland; Tim J M Welting; Jan Willem Voncken Journal: Cartilage Date: 2018-04-09 Impact factor: 4.634
Authors: Rafael Menezes-Reis; Carlos E Garrido Salmon; Gustavo P Bonugli; Debora Mazoroski; Mauricio H Tamashiro; Leonor G Savarese; Marcello Henrique Nogueira-Barbosa Journal: Quant Imaging Med Surg Date: 2016-08
Authors: Oscar Alvarez-Garcia; Tokio Matsuzaki; Merissa Olmer; Koichi Masuda; Martin K Lotz Journal: J Orthop Res Date: 2017-05-04 Impact factor: 3.494